Reuters logo
2 months ago
BRIEF-Immunocellular Therapeutics reports data from ict-121 phase 1 trial in recurrent glioblastoma
June 5, 2017 / 9:07 PM / 2 months ago

BRIEF-Immunocellular Therapeutics reports data from ict-121 phase 1 trial in recurrent glioblastoma

June 5 (Reuters) - Immunocellular Therapeutics Ltd:

* Immunocellular Therapeutics announces data from ict-121 phase 1 trial in recurrent glioblastoma at asco 2017

* Immunocellular Therapeutics Ltd- ‍ict-121 was generally safe and well tolerated​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below